Avidity Biosciences Reports Fourth Quarter and Year-End 2021

/PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody...

Related Keywords

San Diego , California , United States , Cherise Adkins , Steve Hughes , Kathleen Gallagher , Mike Maclean , Eli Lilly , Sarah Boyce , Linkedin , Twitter , Company Contact , Prnewswire Avidity Biosciences Inc , Nasdaq , Exchange Commission , Development Rd Expenses , Clinical Trial Research Network , European Medicines Agency , Avidity Biosciences Inc , Antibody Oligonucleotide Conjugates , Duchenne Muscular Dystrophy , Trial Research Network , Motor Outcomes , Validate Evaluations Plus , Cash Equivalents , Marketable Securities , Oligonucleotide Conjugates , Private Securities Litigation Reform Act , Avidity Biosciences , Nc ,